UNITE4TB

As the year draws to a close, we're happy to share the latest edition of the UNITE4TB Newsletter, packed full of updates and insights on our ongoing efforts to accelerate the development of new treatment regimens for tuberculosis (TB). In this issue: 🔹 UNITE4TB project lead, Derek Sloan, reflects on the year that has been and how the work of the Consortium is reshaping the global TB landscape 🔹 We provide an update on the status of the UNITE4TB clinical trial program 🔹 We look back at our collaboration with PAN-TB at this year's Union Conference 🔹 We proudly share our joint call for sustained investment in TB and antibiotic research These stories and more! 🔗👉 https://lnkd.in/ghPw7zhB Subscribe to our newsletter for the latest news and updates (see link in comments) #UNITE4TB #EndTB #GlobalHealth #Newsletter #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). Proud partner of the AMR Accelerator. In partnership with: Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lygature, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, Centre Multidisciplinary Research in Health Science , School of Medicine, University of St Andrews, University of St Andrews, Farmaceutiska fakulteten • Uppsala universitet, Uppsala University, European Respiratory Society, TBnet, GSK, Johnson & Johnson, Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research

🌍 Collaborating to Transform TB Drug Development 🤝 UNITE4TB proudly joined forces with the PAN-TB Collaboration at this year’s Union Conference on Lung Health in Bali to highlight the critical role of collaboration in driving innovation for TB drug development. The session featured insights from developers, policymakers, and community representatives, emphasizing the challenges and opportunities in the new regimen development process. Read more 👉 https://lnkd.in/evz2wRp7 #UNITE4TB #PANTB #UnionConf2024 #tuberculosis #EndTB #PublicPrivatePartnership Innovative Health Initiative (IHI), AMR Accelerator, Jodie Schildkraut, Barros David, Paul Sommerfeld, Maria Tarcela Gler, Fuad Mirzayev, David Holtzman, Bill & Melinda Gates Medical Research Institute

📢Have you registered yet for the fourth and final #UNITE4TB #webinar of 2024? The webinar will feature a discussion on intersecting the vulnerabilities of TB in migrants: prevention and care strategies Speaker: Dr Jessica Potter (London, United Kingdom) Date and time: 28 November, 13:00–14:00 CET Find out more and register 👉 https://lnkd.in/e569YrMg ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society, Innovative Health Initiative (IHI), AMR Accelerator

PARADIGM4TB Update As part of the UNITE4TB Phase 2B/C clinical trial program, the PARADIGM4TB trial is setting new standards in TB research. In a recent interview, Dr. Ilaria Motta from the MRC Clinical Trials Unit at UCL shared insights into the trial's progress, challenges, and future milestones. 💡 Key Highlights:  - PARADIGM4TB is a platform trial evaluating innovative combinations of TB treatments, aiming to shorten development timelines. - Since January, 100 participants have been enrolled across sites in South Africa, Tanzania, and Uganda, with plans to expand to Asia, Europe, and South America in 2025. - The trial represents a collaborative effort to not only develop novel therapies but also to redefine how TB trials are conducted. Read the full interview 👉 https://lnkd.in/eXa6gz7f #UNITE4TB #ClinicalTrials #PARADIGM4TB #GlobalHealth #PublicPrivatePartership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI). AMR Accelerator UCL

📢PAN-TB Collaboration & UNITE4TB at the Union Conference 2024! What does it take to advance a TB drug through complex trials and into public health programs? Hear directly from developers, policymakers, and the community perspective on navigating global trial challenges, including non-clinical requirements for underserved populations and community support for trial assessments. Our Satellite Session at the Union Conference in Bali on 14 November will also showcase how partnerships like the #PANTB Collaboration and #UNITE4TB streamline drug regimen development through collective work – along with an update from the PAN-TB Phase 2b/c trial. More info: http://bit.ly/3NF1C0A #UnionConf2024 #tuberculosis #innovation #EndTB #PublicPrivatePartnership Innovative Health Initiative (IHI), AMR Accelerator, Jodie Schildkraut, Barros David, Paul Sommerfeld, Maria Tarcela Gler, Fuad Mirzayev, David Holtzman

Our 11th #UNITE4TB webinar tackled an essential topic: managing adverse events in TB care. From insights on drug-related challenges to best practices for improving patient outcomes, our speaker Dr. Simon Tiberi of GSK provided valuable strategies for addressing adverse effects and enhancing treatment adherence. Read the highlights here 👉 https://lnkd.in/eBRsPGep #TBCare #HealthInnovation #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society, AMR Accelerator

🌍 Global Action Needed! 🌍 The threat of #AntimicrobialResistance and #Tuberculosis (TB) is growing, but innovative research projects like UNITE4TB are helping to lead the charge in developing new treatments. Under the umbrella of the AMR Accelerator and funded by the Innovative Health Initiative (IHI), UNITE4TB is pushing the boundaries of TB research with cutting-edge clinical trials. Sustainable investment is crucial to continue this life-saving work. Ahead of this year's UN High-Level Meeting on AMR, we join our fellow AMR Accelerator partners in underscoring the urgency of maintaining expertise and capabilities to develop new treatments for AMR, TB, and other infectious diseases. Read more about our efforts in our joint call to action published today in Nature Reviews Drug Discovery 👉 https://lnkd.in/e4-nj_T3 #AMR #TB #GlobalHealth #Innovation #UNGAHLM #WeWontRest UNITE4TB is a #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (now Innovative Health Initiative (IHI)). In partnership with: Radboudumc, London School of Hygiene and Tropical Medicine, U. of London, University of Oxford, Oxford University Clinical Research Unit, Research Center Borstel, Lygature, Lancaster University, UCL, MRC Clinical Trials Unit at UCL, TASK, Libera Università Vita-Salute San Raffaele, Helmholtz Munich, KNCV TB Plus, Critical Path Institute (C-Path), European Lung Foundation, ISPUP | Instituto de Saúde Pública da Universidade do Porto, University of Liverpool, IRD, University of Hamburg, University of California, San Francisco, TB Alliance, FIND, Università degli Studi di Milano, Centre Multidisciplinary Research in Health Science , School of Medicine, University of St Andrews, University of St Andrews, Farmaceutiska fakulteten • Uppsala universitet, Uppsala University, European Respiratory Society, TBnet, GSK, Johnson & Johnson, LMU Munich – Ludwig-Maximilians-Universität München, LMU Klinikum München, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research

📢 Register now for the next UNITE4TB #webinar: Topic: Expert interview: Management of adverse events in TB care Speaker: Dr Simon Tiberi (GSK) Date: 26 September, 13:00–14:00 CEST Educational aims: - To understand the importance of counseling people with TB on adverse events before starting treatment - To evaluate factors that might increase the risk of adverse events and how to monitor them - To learn how to assess and manage adverse events, and if and when to restart TB drugs - To understand the importance of active TB drug safety monitoring Find out more and register 👉 https://lnkd.in/ep8QmQD7 ISPUP | Instituto de Saúde Pública da Universidade do Porto, European Respiratory Society, Innovative Health Initiative (IHI), AMR Accelerator

🚀 Exciting Milestone! UNITE4TB has successfully completed participant recruitment for its DECISION trial. This pivotal Phase 2B study is set to evaluate the safety and efficacy of the novel antibiotic BTZ-043 for drug-sensitive TB. Kudos to our dedicated team and partners for their hard work and commitment to advancing TB treatment. 🌍💊 Learn more about this latest milestone and its potential impact 👉 https://lnkd.in/e3ccJdT9 #YesWeCanEndTB #SaveLives #PublicPrivatePartnership funded by the Innovative Medicines Initiative 2 (Innovative Health Initiative (IHI)). AMR Accelerator, LMU Munich – Ludwig-Maximilians-Universität München, LMU Klinikum München, Michael Hoelscher, EFPIA - European Federation of Pharmaceutical Industries and Associations, German Center for Infection Research

Happening soon! Don't forget to join our #webinar today starting at 13:00 (CEST). More info and the link to register below 👇